BioLamina

About BioLamina

BioLamina specializes in providing high-quality laminin cell culture matrices, which are the only original, full-length, human recombinant laminins available on the market. These products are designed to support the robust expansion, maintenance, and differentiation of human primary cells, making them ideal for both basic research and clinical applications. BioLamina serves a diverse range of clients, including academic researchers, biotech companies, and clinical laboratories, who are engaged in cell culture and cell therapy development. The company operates in the biotechnology market, focusing on cell culture systems that are standardized and clinically compliant. BioLamina's business model revolves around the sale of its proprietary laminin products, which are animal origin-free and come with comprehensive documentation such as Certificates of Analysis and Material Safety Data Sheets. Revenue is generated through direct sales to research institutions and commercial entities involved in cell therapy and regenerative medicine.